Benefits of paricalcitol (Selective vitamin D receptor activator indicated for the prevention and treatment of secondary hyperparathyroidism) on anaemia of inflammation in dialysis patients receiving erythropoiesis-stimulating agents.

Trial Profile

Benefits of paricalcitol (Selective vitamin D receptor activator indicated for the prevention and treatment of secondary hyperparathyroidism) on anaemia of inflammation in dialysis patients receiving erythropoiesis-stimulating agents.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Paricalcitol (Primary)
  • Indications Anaemia
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms PIERIAD STUDY
  • Most Recent Events

    • 02 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top